Cooper Net Total Equity Issued/Repurchased 2010-2025 | COO
Cooper annual/quarterly net total equity issued/repurchased history and growth rate from 2010 to 2025. Net total equity issued/repurchased can be defined as the sum of all preferred and common equity transactions regarding a company's own stock.
- Cooper net total equity issued/repurchased for the quarter ending January 31, 2025 was $-0.006B, a 162.38% decline year-over-year.
- Cooper net total equity issued/repurchased for the twelve months ending January 31, 2025 was $0.081B, a 71.64% increase year-over-year.
- Cooper annual net total equity issued/repurchased for 2024 was $0.064B, a 177.83% increase from 2023.
- Cooper annual net total equity issued/repurchased for 2023 was $0.023B, a 136.86% decline from 2022.
- Cooper annual net total equity issued/repurchased for 2022 was $-0.062B, a 524.49% decline from 2021.
Cooper Annual Net Total Equity Issued/Repurchased
(Millions of US $) |
| 2024 |
$64 |
| 2023 |
$23 |
| 2022 |
$-62 |
| 2021 |
$15 |
| 2020 |
$-32 |
| 2019 |
$-126 |
| 2018 |
$22 |
| 2017 |
$-44 |
| 2016 |
$20 |
| 2015 |
$-48 |
| 2014 |
$-67 |
| 2013 |
$-148 |
| 2012 |
$-16 |
| 2011 |
$82 |
| 2010 |
$11 |
| 2009 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$16.288B |
$3.895B |
|
The Cooper Companies Inc, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision and CooperSurgical. CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company's products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness.?CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians.
|
